Glioblastoma Pipeline Grows as 200+ Pharma Companies Advance Novel Brain Cancer Therapies, Finds DelveInsight | Denovo Biopharma, MediciNova, Tango Therapeutics, BioMimetix

DelveInsight's "Glioblastoma- Pipeline Insight, 2026" report provides comprehensive insights about 200+ companies developing several pipeline drugs in the glioblastoma pipeline landscape. It covers the glioblastoma pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Glioblastoma treatment landscape. Learn more about the evolving glioblastoma pipeline today @ https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Glioblastoma Pipeline Report

• In March 2026, the STELLAR trial reported a >45% survival increase (35 months median OS) with eflornithine + lomustine compared to lomustine alone in recurrent grade 3 IDH-mutant astrocytoma.
• In March 2026, GT Medical Technologies initiated BRIDGES trial enrollment, testing the GammaTile brachytherapy implant post-resection versus standard radiation in newly diagnosed GBM to improve survival.
• In February 2026, IN8bio Phase I/II data showed repeated gamma-delta T-cell therapy yielded 13-month PFS and >17-month OS in newly diagnosed GBM, which reportedly doubles standard care benchmarks.
• In January 2026, a multicenter trial demonstrated that focused ultrasound blood-brain barrier opening combined with temozolomide achieved 13.5-month progression-free survival (PFS) and 31.3-month OS in newly diagnosed GBM.
• In September 2025, NeuroNOS, a Beyond Air subsidiary, received FDA Orphan Drug Designation for BA-101, its investigational therapy for glioblastoma (GBM).
• In November 2025, ImmunityBio Phase 2 QUILT-3.078 reported median overall survival (OS) was not reached in recurrent GBM patients treated with chemo-free ANKTIVA + CAR-NK, bevacizumab, and Optune, also noting that it reverses lymphopenia.
• Glioblastoma is a highly malignant Grade IV primary brain tumor originating from astrocytes, characterized by a poor prognosis despite current multimodal care.
• DelveInsight's report tracks more than 220 pipeline drugs and involves over 200 companies working on clinical and nonclinical stage products for glioblastoma.
• BMX-001, a redox-active small molecule designed to augment tumor killing by radiation, is one of the notable late-stage therapies currently under development.
• DB102 (enzastaurin), an oral kinase inhibitor, is currently in Phase III trials, representing a significant advancement in targeted glioblastoma therapy.
• Mid-stage developments include MDNA55, an "Empowered Superkine" that delivers toxins directly to tumor cells, and MN-166, a glial attenuator that suppresses pro-inflammatory cytokines.
• TNG456 is highlighted as an experimental targeted therapy in Phase I/II trials aiming to inhibit pathways involved in tumor proliferation and immune evasion.
• The leading Glioblastoma companies include Denovo Biopharma, MediciNova, Tango Therapeutics, BioMimetix, and others.
• Therapeutics are being assessed based on several parameters including route of administration, molecule type, and product stage ranging from discovery to Phase III.

Download for updates and the latest revolution in Glioblastoma care @ https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Glioblastoma Emerging Drugs Profile

• DB102 (enzastaurin): Denovo Biopharma
DB102, also known as enzastaurin, is an oral kinase inhibitor currently in Phase III clinical trials. It is being investigated for its potential to provide a targeted approach to treating glioblastoma by inhibiting specific signaling pathways involved in tumor growth.

• MN-166: MediciNova
MN-166 is a mid-stage development candidate characterized as a glial attenuator. Its mechanism of action involves the suppression of pro-inflammatory cytokines, which may help in managing the aggressive environment of glioblastoma tumors.

• TNG456: Tango Therapeutics
TNG456 is an experimental targeted therapy currently in Phase I/II trials. It aims to inhibit specific pathways involved in tumor proliferation and immune evasion, potentially offering a new mechanism for combating glioblastoma.

For more information on the Glioblastoma Emerging Drugs Profile, download DelveInsight's comprehensive Glioblastoma Pipeline Insight report @ https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The Glioblastoma Pipeline Report Provides

• Detailed insights about companies developing therapies for Glioblastoma, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for glioblastoma treatment.
• Glioblastoma companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Glioblastoma drugs under development based on stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the glioblastoma market.

Learn more about Glioblastoma drug opportunities in our comprehensive glioblastoma pipeline report @ https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Glioblastoma Companies and Competitive Landscape

There are 200+ key companies, including Denovo Biopharma, MediciNova, Tango Therapeutics, BioMimetix, and others, developing therapies for glioblastoma, with more than 220 pipeline drugs across various clinical stages.

DelveInsight's Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Glioblastoma products have been categorized under various Molecule types such as:

• Monoclonal antibody
• Small molecule
• Peptide

Discover the latest advancements in Glioblastoma treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Scope of the Glioblastoma Pipeline Report

• Coverage: Global
• Glioblastoma Companies: Denovo Biopharma, MediciNova, Tango Therapeutics, BioMimetix, and others.
• Glioblastoma Therapies: BMX-001, DB102 (enzastaurin), MDNA55, MN-166, TNG456, and other pipeline candidates.
• Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.

This release was published on openPR.